Speciality chemicals major Jubilant Ingrevia Ltd announced on Saturday (March 21) that its wholly owned subsidiary, Jubilant Agro Sciences Limited, has commenced commercial production of Agro Intermediate at its Bharuch site in Gujarat. According to reports from CNBC TV18 and ScanXNews, the production is part of the company's CDMO contract with a leading agrochemical company. Production commenced at 3:38:15 PM (IST) on March 21, 2026, with material dispatches beginning the same day. The announcement was made in compliance with Regulation 30 of SEBI Listing Regulations, ensuring transparency regarding material developments in the company's operations.
The company reported mixed financial results for the third quarter. As reported by CNBC TV18, Jubilant Ingrevia reported a 32.4% year-on-year decline in net profit for Q3 at ₹47 crore, compared with ₹69.4 crore in the same period last year. Revenue remained largely flat, rising 0.5% to ₹1,051 crore from ₹1,056.7 crore in Q3FY25. EBITDA fell 8.5% to ₹126.1 crore from ₹137.9 crore a year ago, with EBITDA margin contracting to 12% from 13% in the corresponding quarter of the previous year.
The board has declared an interim dividend of ₹2.50 per equity share of Re. 1 each on the paid-up equity share capital of the company for the financial year 2025-26. According to CNBC TV18, the Board has fixed Tuesday, February 10, 2026, as the record date to determine the eligibility of shareholders for the interim dividend. The interim dividend will be paid or dispatched on or before March 4, 2026.
The board approved the re-appointment of Ameeta Chatterjee for another term of five years, starting from April 17, 2026, and ending on April 16, 2031, subject to shareholder approval. As reported by CNBC TV18, Ameeta Chatterjee, 51, holds a bachelor's degree in commerce from Lady Shri Ram College for Women, Delhi University, and is a management graduate from the Indian Institute of Management, Bangalore.
Shares of Jubilant Ingrevia Ltd ended at ₹584.75, up by ₹13.55, or 2.37%, on the BSE, according to CNBC TV18. The positive market response reflects investor confidence in the company's operational expansion and strategic developments in the specialty chemicals sector, with the CDMO contract demonstrating the company's capabilities in contract manufacturing services.
